BOSTON SCIENTIFIC TAXUS LIBERTE STENT APPROVED TO TREAT 3 ADDITIONAL INDICATIONS IN EUROPE

Boston Scientific Corp. said it received approval from European regulators for the expanded use of its TAXUS Liberte coronary stent system in three new coronary procedures, which account for more than 20% of all coronary interventions. Trading Markets Live (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/255715/)